AMRX · Amneal Pharmaceuticals, Inc.
$18.15
+0.88 (+5.10%)
At close · Aug 14
Market Cap
$5.66B
Shares
319.35M
Amneal Pharmaceuticals, Inc. Earnings Call Transcripts
Every quarterly earnings call for Amneal Pharmaceuticals, Inc. (AMRX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲3.2%
$545.56M
−$7.61M
'22 Q3
22-11-04
▲13.6%
$609.76M
−$12.03M
'22 Q4
23-03-02
▲12%
$557.54M
−$6.94M
'23 Q1
23-05-05
▲7.1%
$599.05M
$11.92M
'23 Q2
23-08-04
▲13.7%
$620.04M
$9.68M
'23 Q3
23-11-07
▲1.2%
$616.98M
−$98.65M
'23 Q4
24-03-01
▲18.2%
$659.19M
−$91.64M
'24 Q1
24-05-03
▲17.1%
$701.78M
$5.99M
'24 Q2
24-08-09
▲13.3%
$702.47M
−$156,000
'24 Q3
24-11-08
▲18.4%
$730.52M
−$31.08M
'24 Q4
25-02-28
▲5.5%
$695.42M
$12.20M
'25 Q1
25-05-02
▲3.2%
$724.51M
$22.42M
'25 Q2
25-08-05
▲11.7%
$784.51M
$2.37M
'25 Q3
25-10-30
▲11.5%
$814.32M
$35.08M
'25 Q4
26-02-27
▲3.9%
$722.52M
$62.26M
'26 Q1
26-05-01
LATEST
▲9.9%
$796.20M
$57.66M
'26 Q2
26-07-30
Earnings call
FY26 · Q2
2026-07-30
Amneal Pharmaceuticals Second Quarter 2026 Earnings Conference Call
Confident tone
Biosimilars / Kashiv acquisition
Affordable medicines / transdermal patches
Specialty brands
Revenue
$796.20M
▲ 9.9% YoY Diluted EPS
$0.18
▲ 157.1% YoY Gross margin
42.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
Goldman Sachs 47th Annual Global Healthcare Conference 2026
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-01
Amneal Pharmaceuticals, Inc. Q1 FY2026 Earnings Call
Confident tone
Biosimilars market opportunity
Long-term combined company outlook
Gross margin trajectory
Revenue
$722.52M
▲ 3.9% YoY Diluted EPS
$0.19
▲ 375% YoY Gross margin
44.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-10
Barclays 28th Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-27
Amneal Pharmaceuticals, Inc. Q4 FY2025 Earnings Call
Confident tone
Specialty / Crexone (Krexone) Parkinson's launch
Affordable Medicines / Complex Generics
Biosimilars
Revenue
$814.32M*
▲ 11.5% YoY Gross margin
36.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-30
Amneal Pharmaceuticals, Inc. Q3 FY2025 Earnings Call
Confident tone
Biosimilars pipeline
GLP-1 collaboration with Metsera
CREXONT (Parkinson's disease)
Revenue
$784.51M
▲ 11.7% YoY Diluted EPS
$0.01
Gross margin
34.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Amneal Pharmaceuticals, Inc. Q2 FY2025 Earnings Call
Confident tone
CREXONT Parkinson's launch
Brekiya autoinjector launch
Affordable Medicines / injectables
Revenue
$724.51M
▲ 3.2% YoY Diluted EPS
$0.07
▲ 250% YoY Gross margin
39.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-02
Amneal Pharmaceuticals, Inc. Q1 FY2025 Earnings Call
Confident tone
Affordable Medicines / injectables and biosimilars
CREXONT launch momentum and market access
U.S. manufacturing footprint and tariffs
Revenue
$695.42M
▲ 5.5% YoY Diluted EPS
$0.04
Gross margin
36.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-28
Amneal Pharmaceuticals, Inc. Q4 FY2024 Earnings Call
Confident tone
Crexent launch and specialty growth
Biosimilars pipeline
GLP-1 / Medcera weight loss collaboration
Revenue
$730.52M*
▲ 18.4% YoY Gross margin
36.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-08
Amneal Pharmaceuticals, Inc. Q3 FY2024 Earnings Call
Confident tone
CREXONT launch (Parkinson's)
GLP-1 / Obesity (Metsera collaboration)
Affordable Medicines / Generic segment
Revenue
$702.47M
▲ 13.3% YoY Diluted EPS
$0.00
▼ 100% YoY Gross margin
38.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-09
Amneal Pharmaceuticals, Inc. Q2 FY2024 Earnings Call
Confident tone
Affordable Medicines / Generic segment growth
CREXONT approval and launch
Biosimilars pipeline and expansion
Revenue
$701.78M
▲ 17.1% YoY Diluted EPS
$0.02
▼ 75% YoY Gross margin
35.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-03
Amneal Pharmaceuticals, Inc. Q1 FY2024 Earnings Call
Confident tone
Specialty / Neurology Pipeline
Biosimilars Opportunity
Injectables and Drug Shortages
Revenue
$659.19M
▲ 18.2% YoY Diluted EPS
$-0.30
Gross margin
36.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-01
Amneal Pharmaceuticals, Inc. Q4 FY2023 Earnings Call
Confident tone
Specialty / Neurology Pipeline
Generics and Injectables Growth
Biosimilars Expansion
Revenue
$616.98M*
▲ 1.2% YoY Gross margin
30.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Amneal Pharmaceuticals, Inc. Q3 FY2023 Earnings Call
Revenue
$620.04M
▲ 13.7% YoY Diluted EPS
$0.06
Gross margin
37.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-04
Amneal Pharmaceuticals, Inc. Q2 FY2023 Earnings Call
Revenue
$599.05M
▲ 7.1% YoY Diluted EPS
$0.08
Gross margin
36.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-05
Amneal Pharmaceuticals, Inc. Q1 FY2023 Earnings Call
Revenue
$557.54M
▲ 12% YoY Diluted EPS
$-0.05
Gross margin
32.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-02
Amneal Pharmaceuticals, Inc. Q4 FY2022 Earnings Call
Revenue
$609.76M*
▲ 13.6% YoY Gross margin
35.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-04
Amneal Pharmaceuticals, Inc. Q3 FY2022 Earnings Call
Revenue
$545.56M
▲ 3.2% YoY Diluted EPS
$-0.02
Gross margin
35.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-05
Amneal Pharmaceuticals, Inc. Q2 FY2022 Earnings Call
Revenue
$559.36M
▲ 4.5% YoY Diluted EPS
$-0.80
▼ 900% YoY Gross margin
35.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Amneal Pharmaceuticals, Inc. Q1 FY2022 Earnings Call
Revenue
$497.63M
▲ 0.9% YoY Diluted EPS
$-0.01
▼ 125% YoY Gross margin
35.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-02
Amneal Pharmaceuticals, Inc. Q4 FY2021 Earnings Call
Revenue
$536.90M*
▲ 5.3% YoY Gross margin
31.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Amneal Pharmaceuticals, Inc. Q3 FY2021 Earnings Call
Revenue
$528.59M
▲ 1.8% YoY Diluted EPS
$-0.03
Gross margin
37.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Amneal Pharmaceuticals, Inc. Q2 FY2021 Earnings Call
Revenue
$535.08M
▲ 15.2% YoY Diluted EPS
$0.10
Gross margin
39.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-07
Amneal Pharmaceuticals, Inc. Q1 FY2021 Earnings Call
Revenue
$493.11M
▼ 1.1% YoY Diluted EPS
$0.04
▼ 94.9% YoY Gross margin
38.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-26
Amneal Pharmaceuticals, Inc. Q4 FY2020 Earnings Call
Revenue
$510.03M*
▲ 28.4% YoY Gross margin
32.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-06
Amneal Pharmaceuticals, Inc. Q3 FY2020 Earnings Call
Revenue
$519.29M
▲ 37.3% YoY Diluted EPS
$-0.06
Gross margin
25.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Amneal Pharmaceuticals, Inc. Q2 FY2020 Earnings Call
Revenue
$464.66M
▲ 14.8% YoY Diluted EPS
$-0.08
Gross margin
31.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
Amneal Pharmaceuticals, Inc. Q1 FY2020 Earnings Call
Revenue
$498.53M
▲ 11.7% YoY Diluted EPS
$0.78
Gross margin
36.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-26
Amneal Pharmaceuticals, Inc. Q4 FY2019 Earnings Call
Revenue
$397.33M
▼ 20.1% YoY Diluted EPS
$-0.23
Gross margin
27.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–29 of 29 earnings calls
Key facts
CIK
1723128
CUSIP
03168L105
13F (30d)
292 filings
288 filers
Visit website
Investor relations